CAR T-Cell Therapy Market (By Drug Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others; By Indication: Lymphoma, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Others; By End User: Hospitals, Cancer Treatment Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. CAR T-Cell Therapy Market, by Drug Type, 2023-2032
8.1.1 Axicabtagene Ciloleucel
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Tisagenlecleucel
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Brexucabtagene Autoleucel
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2020-2032)
9.1. CAR T-Cell Therapy Market, by Indication, 2023-2032
9.1.1. Lymphoma
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Acute Lymphocytic Leukemia
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Chronic Lymphocytic Leukemia (CLL)
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Multiple Myeloma (MM)
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
10.1. CAR T-Cell Therapy Market, by End User, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Cancer Treatment Centers
10.1.2.1. Market Revenue and Forecast (2020-2032)
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.3. Market Revenue and Forecast, by End User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End User (2020-2032)
12.1. Kolon TissueGene, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. JCR Pharmaceuticals Co., Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Kolon TissueGene, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. JCR Pharmaceuticals Co., Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. MEDIPOST
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. PHARMICELL Co., Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. ANTEROGEN. CO., LTD
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novartis AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gilead Sciences, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample